NCT00077922View on ClinicalTrials.gov

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
LeukemiaLymphocyticChronic
Interventions
DRUG

LMB-2

40 micrograms/kg every other day (QOD) x 3 every 4 weeks

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00077922 - Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter